BACKGROUND: Positron emission tomography (PET) can localize and quantify neurokinin-1 (NK(1)) receptors in brain using the nonpeptide antagonist radioligand, [(18)F]SPA-RQ. We sought to determine if patients with panic disorder have altered density of NK(1) receptors in brain because of their history of recurrent panic attacks. We also sought to determine if a drug-induced panic attack releases substance P in brain, as measured by decreased binding of [(18)F]SPA-RQ. METHODS: Positron emission tomography scans with [(18)F]SPA-RQ were performed in 14 patients with panic disorder and 14 healthy subjects. Of these two groups, 7 patients and 10 healthy subjects were scanned twice, once at baseline and once after injection of doxapram, a drug that induces panic attacks. RESULTS: NK(1) receptor binding in patients (n = 14) compared with that in healthy subjects (n = 14) was significantly decreased by 12% to 21% in all brain regions. Doxapram effectively produced panic attacks in 6 of 7 patients with panic disorder but only 2 of 10 healthy subjects. Doxapram caused no significant change of [(18)F]SPA-RQ binding in either patients or healthy subjects. CONCLUSIONS: Although induction of a panic attack has no significant effect on [(18)F]SPA-RQ binding to NK(1) receptors, patients with panic disorder have widespread reduction of NK(1) receptor binding in brain.
BACKGROUND: Positron emission tomography (PET) can localize and quantify neurokinin-1 (NK(1)) receptors in brain using the nonpeptide antagonist radioligand, [(18)F]SPA-RQ. We sought to determine if patients with panic disorder have altered density of NK(1) receptors in brain because of their history of recurrent panic attacks. We also sought to determine if a drug-induced panic attack releases substance P in brain, as measured by decreased binding of [(18)F]SPA-RQ. METHODS: Positron emission tomography scans with [(18)F]SPA-RQ were performed in 14 patients with panic disorder and 14 healthy subjects. Of these two groups, 7 patients and 10 healthy subjects were scanned twice, once at baseline and once after injection of doxapram, a drug that induces panic attacks. RESULTS:NK(1) receptor binding in patients (n = 14) compared with that in healthy subjects (n = 14) was significantly decreased by 12% to 21% in all brain regions. Doxapram effectively produced panic attacks in 6 of 7 patients with panic disorder but only 2 of 10 healthy subjects. Doxapram caused no significant change of [(18)F]SPA-RQ binding in either patients or healthy subjects. CONCLUSIONS: Although induction of a panic attack has no significant effect on [(18)F]SPA-RQ binding to NK(1) receptors, patients with panic disorder have widespread reduction of NK(1) receptor binding in brain.
Authors: Olof Solin; Olli Eskola; Terence G Hamill; Jörgen Bergman; Pertti Lehikoinen; Tove Grönroos; Sarita Forsback; Merja Haaparanta; Tapio Viljanen; Christine Ryan; Raymond Gibson; Gerard Kieczykowski; Jarmo Hietala; Richard Hargreaves; H Donald Burns Journal: Mol Imaging Biol Date: 2004 Nov-Dec Impact factor: 3.488
Authors: M S Kramer; N Cutler; J Feighner; R Shrivastava; J Carman; J J Sramek; S A Reines; G Liu; D Snavely; E Wyatt-Knowles; J J Hale; S G Mills; M MacCoss; C J Swain; T Harrison; R G Hill; F Hefti; E M Scolnick; M A Cascieri; G G Chicchi; S Sadowski; A R Williams; L Hewson; D Smith; E J Carlson; R J Hargreaves; N M Rupniak Journal: Science Date: 1998-09-11 Impact factor: 47.728
Authors: M K Shear; P Rucci; J Williams; E Frank; V Grochocinski; J Vander Bilt; P Houck; T Wang Journal: J Psychiatr Res Date: 2001 Sep-Oct Impact factor: 4.791
Authors: Thomas Dresler; Anne Guhn; Sara V Tupak; Ann-Christine Ehlis; Martin J Herrmann; Andreas J Fallgatter; Jürgen Deckert; Katharina Domschke Journal: J Neural Transm (Vienna) Date: 2012-06-13 Impact factor: 3.575
Authors: Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer Journal: World J Biol Psychiatry Date: 2016-07-15 Impact factor: 4.132
Authors: Sanjay J Mathew; Meena Vythilingam; James W Murrough; Carlos A Zarate; Adriana Feder; David A Luckenbaugh; Becky Kinkead; Michael K Parides; David G Trist; Massimo S Bani; Paolo U Bettica; Emiliangelo M Ratti; Dennis S Charney Journal: Eur Neuropsychopharmacol Date: 2010-12-30 Impact factor: 4.600
Authors: Johanna M Jarcho; Natasha A Feier; Alberto Bert; Jennifer A Labus; Maunoo Lee; Jean Stains; Bahar Ebrat; Stephanie M Groman; Kirsten Tillisch; Arthur L Brody; Edythe D London; Mark A Mandelkern; Emeran A Mayer Journal: Pain Date: 2013-03-05 Impact factor: 6.961
Authors: A Frick; F Åhs; Å M Palmquist; A Pissiota; U Wallenquist; M Fernandez; M Jonasson; L Appel; Ö Frans; M Lubberink; T Furmark; L von Knorring; M Fredrikson Journal: Mol Psychiatry Date: 2015-12-01 Impact factor: 15.992
Authors: A Frick; F Ahs; C Linnman; M Jonasson; L Appel; M Lubberink; B Långström; M Fredrikson; T Furmark Journal: Transl Psychiatry Date: 2015-07-07 Impact factor: 6.222